MedTrace Logo

Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction

NCT03534037 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2020-04-28

No results posted yet for this study

Summary

Hyperuricemia is an additional risk factor for cardiovascular disease, associating with left ventricular diastolic dysfunction in individuals with metabolic syndrome. The effect of urate-lowering therapies on left ventricular diastolic dysfunction remains unclear. The study is conducted to investigate whether febuxostat or benzbromarone might improve left ventricular diastolic dysfunction in individuals with metabolic syndrome and hyperuricemia

Conditions

  • Hyperuricemia
  • Metabolic Syndrome
  • Left Ventricular Diastolic Dysfunction

Interventions

DRUG

Febuxostat 40 mg

Febuxostat 40 mg orally per day plus dietary control only

DRUG

Benzbromarone 50mg

Benzbromarone 50mg orally per day plus dietary control only

OTHER

Control

Dietary control only

Sponsors & Collaborators

  • National Defense Medical Center, Taiwan

    lead OTHER

Principal Investigators

  • Cheng-Wei Liu, M.D. · 1.Tri-service General hospital, Songshan branch, Taipei, Taiwan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03534037 on ClinicalTrials.gov